

EMA/532125/2021

European Medicines Agency decision P/0399/2021

of 30 September 2021

on the agreement of a paediatric investigation plan and on the granting of a waiver for ravulizumab (Ultomiris), (EMA-001943-PIP02-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0399/2021

of 30 September 2021

on the agreement of a paediatric investigation plan and on the granting of a waiver for ravulizumab (Ultomiris), (EMA-001943-PIP02-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by Alexion Europe SAS on 13 July 2020 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 September 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for ravulizumab (Ultomiris), concentrate for solution for infusion, solution for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A waiver for ravulizumab (Ultomiris), concentrate for solution for infusion, solution for injection, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/0199/2017 issued on 14 July 2017 and in the decision P/0034/2017 issued on 30 January 2017, including subsequent modifications thereof.

Article 4

This decision is addressed to Alexion Europe SAS, 103-105 Rue Anatole France, 92300 - Levallois-Perret, France.

EMA/PDCO/337064/2021
Amsterdam, 10 September 2021

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a waiver

EMA-001943-PIP02-20

Scope of the application

Active substance(s):

Ravulizumab

Invented name:

Ultomiris

Condition(s):

Treatment in haematopoietic stem cell transplantation

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Concentrate for solution for infusion

Solution for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Alexion Europe SAS

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Alexion Europe SAS submitted for agreement to the European Medicines Agency on 13 July 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 18 August 2020.

Supplementary information was provided by the applicant on 1 June 2021.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
 - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment in haematopoietic stem cell transplantation

The waiver applies to:

- the paediatric population from birth to less than 28 days of age;
- concentrate for solution for infusion, solution for injection, intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment in haematopoietic stem cell transplantation

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with haematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 28 days to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Concentrate for solution for infusion

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	2	Study 1 (ALXN1210-TMA-314): Open-label, single-arm trial to evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of ravulizumab as add-on to best supportive care (BSC) in paediatric patients from 28 days to less than 18 years of age with thrombotic microangiopathy (TMA) after

		haematopoietic stem cell transplantation (HSCT) Study 2 (ALXN1210-TMA-313): Double-blind, randomised, placebo-controlled trial to evaluate efficacy and safety of ravulizumab in adolescents from 12 years to less than 18 years of age (and adults) with thrombotic microangiopathy (TMA) after haematopoietic stem cell transplantation (HSCT)
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By November 2024
Deferral for one or more measures contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of paroxysmal nocturnal haemoglobinuria (PNH)

Authorised indication(s):

- Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (PNH):
 - in patients with haemolysis with clinical symptom(s) indicative of high disease activity;
 - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.

2. Treatment of haemolytic uremic syndrome (aHUS)

Authorised indication(s):

Ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Authorised pharmaceutical form(s):

Concentrate for solution for infusion

Authorised route(s) of administration:

Intravenous use